İlhan AFŞAR, Berna GÖNÜL, Aslı Gamze ŞENER, Metin TÜRKER

In-vitro susceptibility of clinical isolated of Escherichia coli to fosfomycin trometamol and other antibiotics

Komplikasyonsuz üriner sistem infeksiyonlarında en sık izole edilen mikroorganizma E.coli'dir. Fosfomisin trometamol bu infeksiyonlarda kullanılabilecek iyi bir alternatiftir. Çalışmamızda 236 klinik üriner E.coli izolatında, fosfomisin trometamol duyarlılığı bazı diğer antibiyotiklerle karşılaştırılmıştır. Duyarlı suş oranları imipenem ve amikasin için % 99, fosfomisin için % 97, sefepim için % 87, seftriakson için % 81, amoksisilinlklavulanik asit için % 67, siprofloksasin için % 63, sulfametoksazolltrimetoprim ve sefalotin için % 62, ampisilin için % 32 olarak bulunmuştur. Fosfomisinin etkinliği ile imipenem ve amikasinin etkinliği arasındaki fark anlamsız bulunmuş (p>0.05), fakat bu üç antibiyotik ile diğerleri arasında anlamlı etkinlik farkı saptanmıştır (p

Anahtar Kelimeler:

İdrar yolu enfeksiyonları, Anti-bakteriyel ajanlar, Escherichia coli, Fosfomisin, İmipenem, Amikasin, Mikrobiyal duyarlılık testleri, Trometamin

Escherichia coli'nin klinik izolatlarının fosfomisin trometamol ve diğer antibiyotiklere in-vitro duyarlılığı

Escherichia coli is the most commonly isolated microorganism in uncomplicated urinary tract infections. Among the large number of currently available antimicrobial agents, fosfomycin trometamol is a useful alternative for other antibiotics. We studied the in-vitro susceptibility of 236 clinical urinary isolates ofE.coli to fosfomycin trometamol in comparison with some other antibiotics. The percentages of susceptible strains were found to be 99 %for imipenem and amikacin, 97 % for fosfomycin, 87 %for cefepime, 81 %for ceftriaxone, 67 %for amoxicillinlclavulanic acid, 63 %for ciprofloxacin, 62 %for sulphamethoxazole/trimethoprim and cephalothin, and 32 %for ampicillin. No significant differences were found in the efficacies of fosfomycin, imipenem and amikacin (p>0.05) and these three antibiotics were found significantly more active than others (p<0.001).

Keywords:

Urinary Tract Infections, Anti-Bacterial Agents, Escherichia coli, Fosfomycin, Imipenem, Amikacin, Microbial Sensitivity Tests, Tromethamine,

PDF

___

1. Bergan T: Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity, Infection 1990;18(Suppl 2):S65-9.
2. Crocchiolo P: Single-dose fosfomycin trometamol versus multipledose cotrimoxazole in the treatment of lower urinary tract infections in general practice, Chemotherapy 1990;36 (Suppl 1):37-40.
3. Davis RH, Dowd TCO, Holmes W, Smail J, Slack RCB: A comparative double-blind randomised study of single dose fosfomycin trometamol with trimethoprim in the treatment of urinary tract infections in general practice, Chemotherapy 1990;36(Suppl 1):34-6.
4. Kahlmeter G: The ECO-SENS Project. A prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report, J Antimicrob Chemother 2000;46(Supp l):15-22.
5. Naber KG, Thyroff-Friesinger U: Fosfomycin trometamol versus ofloxacin/ co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: A multicentre study, Infection 1990;18(Suppl 2):70-6.
6. Naber KG, Thyroff-Friesinger U: Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single dose therapy with fosfomycin trometamol versus ofloxacin/co-trimoxazole, Infection 1992;20(Suppl 4):296-301.
7. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests, Approved standard, Document M2-A4, NCCLS, Villanova, PA (1993).
8. Neu HC: Fosfomycin trometamol versus amoxycillin-single-dose multicenter study of urinary tract infections, Chemotherapy 1990;36(Suppl 1):19-23.
9. Nicolle LE: Empirical treatment of acute cystitis in women, Int J Antimicrob Agents 2003;22(1):1-6.
10. Reeves DS: Fosfomycin trometamol, J Antimicrob Chemother 1994; 34(6):853-8.
11. Slack R, Grenwood D: The microbiological and pharmacokinetic profile of an antibacterial agent useful for the single-dose therapy of urinary tract infection, Eur Urol 1987;(Suppl 13):32-6.
12. Stein GE: Single-dose treatment of acute cystitis with fosfomycin tromethamine, Ann Pharmacother 1998;32(2):215-9.
13. Stein GE, Pharm D: Fosfomycin tromethamine: Single-dose treatment of acute cystitis, Int J Fertil 1999;44(2):104-9.
14. Ungheri D, Albini E, Belluco G: In vitro susceptibility of quinoloneresistant clinical isolates of Escherichia coli to fosfomycin trometamol,J Chemother 2002;14(3):237-40.